Faculty Opinions recommendation of Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease.

2014 ◽  
Author(s):  
David Griffith
Keyword(s):  
Pulmonary Disease ◽  
Mycobacterium Abscessus

scholarly journals Impact of susceptibility to injectable antibiotics on the treatment outcomes of Mycobacterium abscessus pulmonary disease

2021 ◽  
Author(s):  
Youngmok Park ◽  
Yea Eun Park ◽  
Byung Woo Jhun ◽  
Jimyung Park ◽  
Nakwon Kwak ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Pulmonary Disease ◽  
Drug Susceptibility ◽  
Mycobacterium Abscessus ◽  
Beta Lactams ◽  
In Vitro Susceptibility ◽  
Referral Hospitals ◽  
Microbiological Cure ◽  
Culture Conversion

Abstract Objectives Current guidelines recommend a susceptibility-based regimen for Mycobacterium abscessus subspecies abscessus pulmonary disease (MAB-PD), but the evidence is weak. We aimed to investigate the association between treatment outcomes and in vitro drug susceptibility to injectable antibiotics in MAB-PD patients. Methods We enrolled MAB-PD patients treated with intravenous amikacin and beta-lactams for ≥4 weeks at four referral hospitals in Seoul, South Korea. Culture conversion and microbiological cure at one year were evaluated based on susceptibility to injectable antibiotics among patients treated with those antibiotics for ≥ 2 weeks. Results A total of 82 patients were analysed. The mean age was 58.7 years, and 65.9% were women. Sputum culture conversion and microbiological cure were achieved in 52.4% and 41.5% of patients, respectively. Amikacin was the most common agent to which the M. abscessus subspecies abscessus isolates were susceptible (81.7%); 9.8% and 24.0% of the isolates were resistant to cefoxitin and imipenem, respectively. The clarithromycin-inducible resistance (IR) group (n = 65) had a lower microbiological cure rate than the clarithromycin-susceptible group (35.4% vs. 64.7%). The treatment outcomes appeared to be similar regardless of in vitro susceptibility results with regard to intravenous amikacin, cefoxitin, imipenem, and moxifloxacin. In the subgroup analysis of the clarithromycin-IR group, the treatment outcomes did not differ according to antibiotic susceptibility. Conclusions We did not find evidence supporting the use of susceptibility-based treatment with intravenous amikacin and beta-lactams in patients with MAB-PD. Further research would be required.

Clinical and Radiographic Characteristics of 12 Patients with Mycobacterium abscessus Pulmonary Disease

2003 ◽  
Vol 54 (1) ◽  
pp. 45 ◽  
Author(s):  
Won Jung Koh ◽  
O Jung Kwon ◽  
Eun Hae Kang ◽  
Ik Soo Jeon ◽  
Yu Jang Pyun ◽  
...  
Keyword(s):  
Pulmonary Disease ◽  
Mycobacterium Abscessus

scholarly journals Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

2020 ◽  
Vol 71 (4) ◽  
pp. 905-913 ◽  
Author(s):  
Charles L Daley ◽  
Jonathan M Iaccarino ◽  
Christoph Lange ◽  
Emmanuelle Cambau ◽  
Richard J Wallace ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Pulmonary Disease ◽  
Healthcare Professionals ◽  
Mycobacterium Abscessus ◽  
Clinical Microbiology Laboratory ◽  
Pulmonary Medicine ◽  
Assessment Development ◽  
Evaluation Approach ◽  
Mycobacterium Xenopi ◽  
Immunodeficiency Virus

Abstract Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

scholarly journals Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

2020 ◽  
Vol 71 (4) ◽  
pp. e1-e36 ◽  
Author(s):  
Charles L Daley ◽  
Jonathan M Iaccarino ◽  
Christoph Lange ◽  
Emmanuelle Cambau ◽  
Richard J Wallace ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Pulmonary Disease ◽  
Healthcare Professionals ◽  
Mycobacterium Abscessus ◽  
Clinical Microbiology Laboratory ◽  
Pulmonary Medicine ◽  
Assessment Development ◽  
Evaluation Approach ◽  
Mycobacterium Xenopi ◽  
Immunodeficiency Virus

Abstract Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

scholarly journals Risk factors for microbiologic failure among Taiwanese adults with Mycobacterium abscessus complex pulmonary disease

2015 ◽  
Vol 48 (4) ◽  
pp. 437-445 ◽  
Author(s):  
Yu-Jung Tung ◽  
Sheikh Omer Bittaye ◽  
Jong-Rung Tsai ◽  
Chun-Yu Lin ◽  
Chung-Hao Huang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Pulmonary Disease ◽  
Mycobacterium Abscessus ◽  
Mycobacterium Abscessus Complex

scholarly journals Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs

2011 ◽  
Vol 105 (5) ◽  
pp. 781-787 ◽  
Author(s):  
Jiwon Lyu ◽  
Hang Jea Jang ◽  
Jin Woo Song ◽  
Chang-Min Choi ◽  
Yeon-Mok Oh ◽  
...  
Keyword(s):  
Pulmonary Disease ◽  
Mycobacterium Abscessus ◽  
Injectable Drugs

scholarly journals Case report on pulmonary disease due to coinfection of Mycobacterium tuberculosis and Mycobacterium abscessus : Difficulty in diagnosis

2017 ◽  
Vol 20 ◽  
pp. 123-124 ◽  
Author(s):  
Celestine Ishiekwene ◽  
Mala Subran ◽  
Monica Ghitan ◽  
Margaret Kuhn-Basti ◽  
Edward Chapnick ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Case Report ◽  
Pulmonary Disease ◽  
Mycobacterium Abscessus

scholarly journals Whole Genome Sequencing of Nontuberculous Mycobacterium (NTM) Isolates from Sputum and Environmental Specimens in Co-Habiting Patients with NTM Pulmonary Disease

2019 ◽  
Author(s):  
Jung-Ki Yoon ◽  
Taek Soo Kim ◽  
Jong-Il Kim ◽  
Jae-Joon Yim
Keyword(s):  
Whole Genome Sequencing ◽  
Pulmonary Disease ◽  
Genome Sequencing ◽  
Genetic Distances ◽  
Mycobacterium Abscessus ◽  
Nontuberculous Mycobacterium ◽  
Whole Genome ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide ◽  
Next Generation Sequencing Ngs

Abstract Background : Nontuberculous mycobacterium (NTM) species are ubiquitous microorganisms. NTM pulmonary disease (NTM-PD) is caused not by human-to-human transmission but by independent environmental acquisition. However, recent studies using next-generation sequencing (NGS) have reported trans-continental spread of Mycobacterium abscessus among patients with cystic fibrosis. Results : We investigated NTM genomes through NGS to examine transmission patterns in three pairs of co-habiting NTM-PD patients who were suspected of patient-to-patient transmission. Three pairs of patients with NTM-PD co-habiting for at least 15 years were enrolled: a mother and a daughter with M. avium PD, a couple with M. intracellulare PD, and a second couple, one of whom was infected with M. intracellulare PD and the other of whom was infected with M. abscessus subsp. massiliense PD. Whole genome sequencing was performed using NTM colonies isolated from patients and environmental specimens. Genetic distances were estimated based on single nucleotide polymorphisms (SNPs) in the NTM genomes. Comparing SNPs in the consensus regions, the minimum pairwise SNP distances of NTM isolates derived from the two pairs of patients infected with the same NTM species were over 10,000. In phylogenetic analysis, the NTM isolates from patients with M. avium PD clustered with isolates from different environmental sources. Conclusions : In conclusion, considering the genetic distances between NTM strains, the likelihood of patient-to-patient transmission in pairs of co-habiting NTM-PD patients without overt immune deficiency is minimal.

Sign in / Sign up

Export Citation Format

Share Document